3[1]Fan W, Everett ET, Tan C, et al. Glucocorticoid-mediated inhibition of taxol induced apoptosis in leiomyosarcoma cells[J].Cell Pharmacol, 1994, 1:205～209
4[2]Mitsiades N, Pouiaki V, Kotoula V, et al. Fas ligand is present in tumors of the ewing's sarcoma family and is cleaved into a soluble form by a metelloproteinase [J]. Am J Pathol,1998, 153(6):1947～1956
5[3]Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape[J]. Science, 1996, 274(5291):1363～1366
6[4]O' Connell J, Bennett MW, O' Sullivan GC, et al, The Fas counterattack: a molecular mechanism of tumor immune privilege[J]. Mol Med, 1997, 3(5):294～300
7[5]von Bernstorff W, Spanjaard RA, Chan AK, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctionai Fas(Apo-1/CD95) receptors and aberrant expression of functional Fas ligand[J]. Surgery, 1999, 125(1):73～84
8[6]Mizutani Y,Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer[J]. J Urol, 1998, 160(2): 571～576
9[7]O' Connell J, Bennett MW, O' Sullivan GC, et al. The Fas counterattack: Cancer as a site of immune privilege [J]. Immunol Today, 1999, 20(1):46～52
10[8]Sato k, Kimura F, Nakamura Y, et al. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand[J].Br J Haematol, 1996, 94(2):379～382
